
On Friday, November 20, 2026, Savara Inc. said the US Food and Drug Administration had told the company it will not take action on the biologics license application (BLA) for molgramostim inhalation solution in autoimmune pulmonary alveolar proteinosis (aPAP) by the November 22 PDUFA target action date. The review is ongoing and the agency has given no revised date, a pause that matters to rare-disease investigators and research offices.
What happened
Savara announced the notice at about 8:30 a.m. Eastern on November 20, according to a Biotech Catalyst Calendar report that quotes the company: the review of the BLA is ongoing and no revised action date has been provided by the agency. TheFly, carried by TipRanks, reported the same day that the FDA would not meet the target date and quoted Chair and CEO Matt Pauls: “We appreciate the FDA’s continued efforts on our application.”
The reports describe a missed goal date with the application still open. They do not describe an approval, and they do not describe a complete response letter. The release states that molgramostim’s safety and efficacy have not been established and that it is not approved by the FDA or any other regulator. According to the same newsletter, Savara shares traded at $4.50 at 10:12 a.m. Eastern, down 13.6% from the previous close of $5.21.
Key details
| Item | Detail |
|---|---|
| Product | Molgramostim inhalation solution (proposed brand name Molbreevi), recombinant human GM-CSF |
| Indication | Autoimmune pulmonary alveolar proteinosis (aPAP) |
| Application | Biologics license application under Priority Review |
| Target action date | November 22, 2026 (a Sunday), moved from August 22, 2026 |
| Status on November 20 | Review ongoing; no revised action date from the FDA |
Background and context
The date had already moved once. On April 15, 2026, Savara announced that the FDA had treated the company’s responses to recent information requests as a major amendment to the BLA, which extended the target date by three months from August 22 to November 22. In that release the company said the agency did not cite any safety, efficacy or manufacturing concerns in its correspondence. Molgramostim also holds Fast Track, Breakthrough Therapy and Orphan Drug designations in the US, orphan designation from the European Medicines Agency, and Innovation Passport and Promising Innovative Medicine designations from the UK Medicines and Healthcare products Regulatory Agency (MHRA).
A PDUFA target action date is the date by which the FDA aims to act on an application; it is a review goal, not a statutory deadline, and the notice leaves the application open. That differs from a complete response letter, which closes the review cycle and states what must be fixed. Priority Review is one of the FDA expedited programs.
The evidence behind the application
The pivotal trial is IMPALA-2, a randomized, double-blind, placebo-controlled phase 3 study sponsored by Savara, registered as NCT04544293 on ClinicalTrials.gov. The registry lists 164 enrolled participants, randomized 1:1 to once-daily inhaled molgramostim or placebo, and a primary endpoint of change from baseline to week 24 in the percent predicted diffusing capacity of the lung for carbon monoxide (DLCO) adjusted for hemoglobin. The study start was May 2021 and the primary completion date November 2023.
The results appeared in the New England Journal of Medicine in 2025 (PubMed 40834301). Of 164 randomized patients, 81 received molgramostim at 300 μg daily for 48 weeks and 83 received placebo. The mean change in DLCO at week 24 was 9.8 percentage points with molgramostim and 3.8 with placebo, an estimated difference of 6.0 points (95% CI 2.5 to 9.4; P below 0.001). At week 48 the changes were 11.6 and 4.7 points. The St. George’s Respiratory Questionnaire total score improved by 11.5 points against 4.9 at week 24 (P=0.007), and the paper reports no significant difference on the activity score at 24 weeks. The share of patients with any adverse event, and with a serious one, was similar between groups. Savara funded the trial.
Reaction
Savara’s own statement is the main reaction on record. Mr. Pauls said the company appreciates the agency’s continued efforts, and the release says Savara looks forward to working with the FDA to complete the review. The market response noted above was a one-day move in the share price, not a regulatory signal.
What it means for researchers, universities and research offices
For investigators in rare lung disease, the practical effect is timing. An open application with no date means no labelled product to cite or compare against, and the IMPALA-2 registry record still shows a status of active, not recruiting, with an estimated completion in May 2027, so follow-up obligations continue.
Research offices supporting sponsor-funded trials should treat the delay as a planning input rather than an outcome. Budgets, site staffing and data-retention schedules for a phase 3 programme depend on the regulatory path, and an extended review can lengthen the period in which sites answer sponsor or agency queries. Offices tracking orphan drug designation products can note that designation and expedited status did not produce a decision on the original schedule. Investigators who cite the phase 3 data in grant applications should cite the peer-reviewed paper and the registry record, and describe molgramostim as investigational. A phase 3 trial result is evidence for a regulator to weigh, not an approval.
What happens next
The FDA has not provided a new action date, so the next dated event is any further communication from the agency. Outside the US, the company said in an April 7 release that the MHRA accepted its marketing authorisation application under Accelerated Review with a 150-day assessment and a decision expected in the fourth quarter of 2026. In the same release it said the EMA’s Committee for Medicinal Products for Human Use is reviewing the European application, with a decision expected in the first quarter of 2027.
Sources
- Savara Inc., “Savara Informed That FDA Will Not Take Action on the Molgramostim BLA,” Business Wire, November 20, 2026
- TheFly via TipRanks, “Savara says US FDA will not meet PDUFA target action date for molgramostim BLA,” November 20, 2026
- Biotech Catalyst Calendar, “Savara molgramostim: FDA will not act by Nov. 22 target date,” November 2026
- Savara Inc. via BioSpace, FDA extends review period, April 16, 2026
- Savara Inc. via BioSpace, MHRA accepts the marketing authorisation application, April 7, 2026
- ClinicalTrials.gov, NCT04544293 (IMPALA-2), updated November 18, 2026
- Trapnell BC et al., New England Journal of Medicine, 2025, via PubMed







